Cheng S, Zhang S, Huang M, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med (Lausanne). 2024;11:1411278.

Article  PubMed  Google Scholar 

Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mettu PS, Allingham MJ, Cousins SW. Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906.

Article  PubMed  CAS  Google Scholar 

Empeslidis T, Storey M, Giannopoulos T, et al. How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview Adv Ther. 2019;36(7):1532–48.

PubMed  CAS  Google Scholar 

Zhu L, Parker M, Enemchukwu N, et al. Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun Biol. 2020;3(1):386.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nguyen VP, Henry J, Zhe J, et al. Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits. Exp Eye Res. 2022;223: 109215.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang Z, Shen MM, Fu Y. Combination of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance in neovascular AMD by inhibiting arteriolar choroidal neovascularization. Invest Ophthalmol Vis Sci. 2022;63(12):2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

LeBlanc ME, Wang W, Chen X, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med. 2017;214(4):1029–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ji L, Waduge P, Wan W, et al. Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization. FEBS J. 2022;289(12):3521–34.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dai C, Waduge P, Ji L, et al. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cell Mol Life Sci. 2022;79(1):63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ji L, Waduge P, Hao L, et al. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization. FASEB J. 2022;36(1): e22106.

Article  PubMed  CAS  Google Scholar 

Ji L, Waduge P, Wu Y, et al. Secretogranin III selectively promotes vascular leakage in the deep vascular plexus of diabetic retinopathy. Int J Mol Sci. 2023;24(13):10531.

Article  PubMed  PubMed Central  CAS  Google Scholar 

LeBlanc ME, Wang W, Ji Y, et al. Secretogranin III as a novel target for the therapy of choroidal neovascularization. Exp Eye Res. 2019;181:120–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tang F, LeBlanc ME, Wang W, et al. Anti-Secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis. 2019;22(3):369–82.

Article  PubMed  PubMed Central  CAS  Google Scholar 

He Y, Tian H, Dai C, et al. Optimal efficacy and safety of humanized anti-Scg3 antibody to alleviate oxygen-induced retinopathy. Int J Mol Sci. 2021;23(1):350.

Article  PubMed  PubMed Central  Google Scholar 

Huang C, Waduge P, Kaur A, et al. Optimal humanized Scg3-neutralizing antibodies for anti-angiogenic therapy of diabetic retinopathy. Int J Mol Sci. 2024;25(17):9507.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huang C, Ji L, Kaur A, et al. Anti-Scg3 gene therapy to treat choroidal neovascularization in mice. Biomedicines. 2023;11(7):1910.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851–8.

Article  PubMed  CAS  Google Scholar 

Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol. 2011;55(4–5):383–8.

PubMed  Google Scholar 

Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563–84.

Article  PubMed  CAS  Google Scholar 

Sapieha P. Eyeing central neurons in vascular growth and reparative angiogenesis. Blood. 2012;120(11):2182–94.

Article  PubMed  CAS  Google Scholar 

Milde F, Lauw S, Koumoutsakos P, Iruela-Arispe ML. The mouse retina in 3D: quantification of vascular growth and remodeling. Integr Biol (Camb). 2013;5(12):1426–38.

Article  PubMed  Google Scholar 

Grunewald M, Kumar S, Sharife H, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. 2021;373(6554):eabc8479.

Article  PubMed  CAS  Google Scholar 

Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24(11):816–34.

Article  PubMed  Google Scholar 

Picciotti P, Torsello A, Wolf FI, Paludetti G, Gaetani E, Pola R. Age-dependent modifications of expression level of VEGF and its receptors in the inner ear. Exp Gerontol. 2004;39(8):1253–8.

Article  PubMed  CAS  Google Scholar 

Di Nisio V, Rossi G, Chiominto A, Pompili E, Cecconi S. Do aging and parity affect VEGF-A/VEGFR content and signaling in the ovary?-A mouse model study. Int J Mol Sci. 2023;24(4):3318.

Article  PubMed  PubMed Central  Google Scholar 

Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90(22):10705–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Béliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003;14(1):334–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fu Y, Zhang Z, Webster KA, Paulus YM. Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization. Biomolecules. 2024;14(3):252.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48(11):2229–39.

Article  PubMed